BARUTTA, Federica
BARUTTA, Federica
SCIENZE MEDICHE
Anti-HSP70 levels and the metabolic syndrome: the Casale Monferrato Study
2012-01-01 Lorenzati B; Giunti S; Barutta F; PInach S; Cavallo Perin P; Bruno G; Gruden G
Association of serum MicroRNA-145-5p levels with microvascular complications of type 1 Diabetes: The EURODIAB prospective complications study
2022-01-01 Barutta, Federica; Bellini, Stefania; Guarrera, Simonetta; Matullo, Giuseppe; Schalkwijk, Casper; Stehouwer, Coen D; Chaturvedi, Nish; Soedamah-Muthu, Sabita S; Durazzo, Marilena; Gruden, Gabriella
Associazione tra anti-HSP70 e sindrome plurimetabolica: il Casale Monferrato Study
2012-01-01 Lorenzati B; Giunti S; Barutta F; Pinach S; Amione C; Tricarico M; Landi A; Schimmenti A; Cavallo Perin P; Bruno G; Gruden G
ATTIVAZIONE DEL RECETTORE CB2 E NEFROPATIA DIABETICA SPERIMENTALE
2010-01-01 Barutta F; Gambino R; Pinach S; Cavallo Perin P; Gruden G
Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy
2010-01-01 Barutta F; Corbelli A; Mastrocola R; Gambino R; Di Marzo V; Pinach S; Rastaldi MP; Perin PC; Gruden G.
Cannabinoid Receptors in Diabetic Kidney Disease
2018-01-01 Barutta F.; Mastrocola R.; Bellini S.; Bruno G.; Gruden G.
Circulating anti-Hsp70 levels in nascent metabolic syndrome: the Casale Monferrato Study.
2013-01-01 Gruden G; Barutta F; Pinach S; Lorenzati B; Cavallo-Perin P; Giunti S; Bruno G.
Co-activator-associated arginine methyltransferase 1 (CARM1) is overexpressed in type 2 diabetes.
2017-01-01 Porta, M; Amione, C; Barutta, F; Albano, L; Ciccarelli, M; Fornengo, P; Merlo, S; Ungaro, P; Beguinot, F; Berchialla, P; Cavallo, F; Trento, M.
Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice
2014-01-01 Barutta F; Grimaldi S; Franco I; Bellini S; Gambino R; Pinach S; Corbelli A; Bruno G; Rastaldi MP; Aveta T; Hirsch E; Di Marzo V; Gruden G
Deletion of RAGE fails to prevent hepatosteatosis in obese mice due to impairment of other AGEs receptors and detoxifying systems
2021-01-01 Wouters K.; Cento A.S.; Gaens K.H.; Teunissen M.; Scheijen J.L.J.M.; Barutta F.; Chiazza F.; Collotta D.; Aragno M.; Gruden G.; Collino M.; Schalkwijk C.G.; Mastrocola R.
Diabetes-specific variables associated with quality of life changes in young diabetic people: the type 1 diabetes Registry of Turin (Italy)
2013-01-01 M. Trento; F. Panero;M. Porta;G. Gruden;F. Barutta;F. Cerutti;R. Gambino;M. Perotto;P. Cavallo Perin;G. Bruno
Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”
2020-01-01 Pugliese G.; Penno G.; Natali A.; Barutta F.; Di Paolo S.; Reboldi G.; Gesualdo L.; De Nicola L.
Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”
2019-01-01 Pugliese G.; Penno G.; Natali A.; Barutta F.; Di Paolo S.; Reboldi G.; Gesualdo L.; De Nicola L.
Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy
2017-01-01 Barutta, Federica; Grimaldi, Serena; Gambino, Roberto; Vemuri, Kiran; Makriyannis, Alexandros; Annaratone, Laura; di Marzo, Vincenzo; Bruno, Graziella; Gruden, Gabriella
Early life socioeconomic indicators and the risk of type 1 diabetes in children and young adults
2013-01-01 Bruno G; Spadea T; Picariello R; Gruden G; Barutta F; Cerutti F; Cavallo-Perin p; Costa G; Gnavi R; Piedmont Study Group for Diabetes Epidemiology.
Effect of CB2 Receptor Activation in Experimental Diabetic Nephropathy
2010-01-01 Barutta F; Gambino R; Pinach S; Cavallo Perin P; Gruden G
Effect of CB2 receptor deletion in streptozotocin-induced diabetic mice
2011-01-01 Barutta F; Corbelli A; Pinach S; Rastaldi MP; Cavallo Perin P; Gruden G
Effect of the MCP-1/CCR2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes
2009-01-01 Tarabra E; Giunti S; Barutta F; Salvidio G; Burt D; Deferrari G; Gambino R; Vergola D; Pinach S; Cavallo Perin P; Camussi G; Gruden G.
Effects of CB1 Blockade In Experimental Diabetic Nephropathy
2009-01-01 Barutta F; Giunti S; Mastrocola R; Pinach S; Giardino L; Rastaldi MP; Cavallo Perin P; Gruden G.
Espressione delle Heat Shock Proteins nella nefropatia diabetica sperimentale
2008-01-01 Pinach S; Barutta F; Forbes J; Chiarle R; Giunti S; Arnstein M; Miceli I; Cavallo Perin P; Camussi G; Cooper ME; Gruden G
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Anti-HSP70 levels and the metabolic syndrome: the Casale Monferrato Study | 2012 | Lorenzati B; Giunti S; Barutta F; PInach S; Cavallo Perin P; Bruno G; Gruden G | |
| Association of serum MicroRNA-145-5p levels with microvascular complications of type 1 Diabetes: The EURODIAB prospective complications study | 2022 | Barutta, Federica; Bellini, Stefania; Guarrera, Simonetta; Matullo, Giuseppe; Schalkwijk, Casper; Stehouwer, Coen D; Chaturvedi, Nish; Soedamah-Muthu, Sabita S; Durazzo, Marilena; Gruden, Gabriella | |
| Associazione tra anti-HSP70 e sindrome plurimetabolica: il Casale Monferrato Study | 2012 | Lorenzati B; Giunti S; Barutta F; Pinach S; Amione C; Tricarico M; Landi A; Schimmenti A; Cavallo Perin P; Bruno G; Gruden G | |
| ATTIVAZIONE DEL RECETTORE CB2 E NEFROPATIA DIABETICA SPERIMENTALE | 2010 | Barutta F; Gambino R; Pinach S; Cavallo Perin P; Gruden G | |
| Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy | 2010 | Barutta F; Corbelli A; Mastrocola R; Gambino R; Di Marzo V; Pinach S; Rastaldi MP; Perin PC; Gruden G. | |
| Cannabinoid Receptors in Diabetic Kidney Disease | 2018 | Barutta F.; Mastrocola R.; Bellini S.; Bruno G.; Gruden G. | |
| Circulating anti-Hsp70 levels in nascent metabolic syndrome: the Casale Monferrato Study. | 2013 | Gruden G; Barutta F; Pinach S; Lorenzati B; Cavallo-Perin P; Giunti S; Bruno G. | |
| Co-activator-associated arginine methyltransferase 1 (CARM1) is overexpressed in type 2 diabetes. | 2017 | Porta, M; Amione, C; Barutta, F; Albano, L; Ciccarelli, M; Fornengo, P; Merlo, S; Ungaro, P; Beguinot, F; Berchialla, P; Cavallo, F; Trento, M. | |
| Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice | 2014 | Barutta F; Grimaldi S; Franco I; Bellini S; Gambino R; Pinach S; Corbelli A; Bruno G; Rastaldi MP; Aveta T; Hirsch E; Di Marzo V; Gruden G | |
| Deletion of RAGE fails to prevent hepatosteatosis in obese mice due to impairment of other AGEs receptors and detoxifying systems | 2021 | Wouters K.; Cento A.S.; Gaens K.H.; Teunissen M.; Scheijen J.L.J.M.; Barutta F.; Chiazza F.; Collotta D.; Aragno M.; Gruden G.; Collino M.; Schalkwijk C.G.; Mastrocola R. | |
| Diabetes-specific variables associated with quality of life changes in young diabetic people: the type 1 diabetes Registry of Turin (Italy) | 2013 | M. Trento; F. Panero;M. Porta;G. Gruden;F. Barutta;F. Cerutti;R. Gambino;M. Perotto;P. Cavallo Perin;G. Bruno | |
| Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function” | 2020 | Pugliese G.; Penno G.; Natali A.; Barutta F.; Di Paolo S.; Reboldi G.; Gesualdo L.; De Nicola L. | |
| Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function” | 2019 | Pugliese G.; Penno G.; Natali A.; Barutta F.; Di Paolo S.; Reboldi G.; Gesualdo L.; De Nicola L. | |
| Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy | 2017 | Barutta, Federica; Grimaldi, Serena; Gambino, Roberto; Vemuri, Kiran; Makriyannis, Alexandros; Annaratone, Laura; di Marzo, Vincenzo; Bruno, Graziella; Gruden, Gabriella | |
| Early life socioeconomic indicators and the risk of type 1 diabetes in children and young adults | 2013 | Bruno G; Spadea T; Picariello R; Gruden G; Barutta F; Cerutti F; Cavallo-Perin p; Costa G; Gnavi R; Piedmont Study Group for Diabetes Epidemiology. | |
| Effect of CB2 Receptor Activation in Experimental Diabetic Nephropathy | 2010 | Barutta F; Gambino R; Pinach S; Cavallo Perin P; Gruden G | |
| Effect of CB2 receptor deletion in streptozotocin-induced diabetic mice | 2011 | Barutta F; Corbelli A; Pinach S; Rastaldi MP; Cavallo Perin P; Gruden G | |
| Effect of the MCP-1/CCR2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes | 2009 | Tarabra E; Giunti S; Barutta F; Salvidio G; Burt D; Deferrari G; Gambino R; Vergola D; Pinach S; Cavallo Perin P; Camussi G; Gruden G. | |
| Effects of CB1 Blockade In Experimental Diabetic Nephropathy | 2009 | Barutta F; Giunti S; Mastrocola R; Pinach S; Giardino L; Rastaldi MP; Cavallo Perin P; Gruden G. | |
| Espressione delle Heat Shock Proteins nella nefropatia diabetica sperimentale | 2008 | Pinach S; Barutta F; Forbes J; Chiarle R; Giunti S; Arnstein M; Miceli I; Cavallo Perin P; Camussi G; Cooper ME; Gruden G |